Abstract
Short interfering RNAs (siRNAs) are the most commonly used RNA interference (RNAi) triggers. They hold promise as potent therapeutic tools, as demonstrated by recent successful in vivo experiments. However, in addition to triggering intended sequence-specific silencing effects, the reagents of RNAi technology can often cause side effects, including immunological off-target effects. The cellular sensors of foreign RNA, such as RIG-I or Toll-like receptors, involved in innate immune antiviral responses, are activated by RNAi reagents. Stimulation of these pathways results in changes in the cellular transcriptome and proteome that can lead to the inhibition of cell division and growth and eventually apoptosis. An additional undesired effect in the context of research applications may be the misinterpretation of experimental results. To date, a number of the specific features of siRNA structure, sequence and delivery mode that are responsible for these effects have been identified. This knowledge may be helpful in designing safer gene-silencing reagents. In this article we discuss the recent developments in the field of non-specific toxic effects caused by RNAi triggers and their delivery vehicles. These data are critically discussed and evaluated, taking advantage of relevant information compiled in the recently launched RNAimmuno database (http://rnaimmuno.ibch.poznan.pl).
Keywords: Interferon response, non-specific effects, RNAimmuno, RNA interference, siRNA, toxic effects
Current Gene Therapy
Title: Recent Advances in Understanding of the Immunological Off-Target Effects of siRNA
Volume: 11 Issue: 6
Author(s): Marta Olejniczak, Katarzyna Polak, Paulina Galka-Marciniak and Wlodzimierz J. Krzyzosiak
Affiliation:
Keywords: Interferon response, non-specific effects, RNAimmuno, RNA interference, siRNA, toxic effects
Abstract: Short interfering RNAs (siRNAs) are the most commonly used RNA interference (RNAi) triggers. They hold promise as potent therapeutic tools, as demonstrated by recent successful in vivo experiments. However, in addition to triggering intended sequence-specific silencing effects, the reagents of RNAi technology can often cause side effects, including immunological off-target effects. The cellular sensors of foreign RNA, such as RIG-I or Toll-like receptors, involved in innate immune antiviral responses, are activated by RNAi reagents. Stimulation of these pathways results in changes in the cellular transcriptome and proteome that can lead to the inhibition of cell division and growth and eventually apoptosis. An additional undesired effect in the context of research applications may be the misinterpretation of experimental results. To date, a number of the specific features of siRNA structure, sequence and delivery mode that are responsible for these effects have been identified. This knowledge may be helpful in designing safer gene-silencing reagents. In this article we discuss the recent developments in the field of non-specific toxic effects caused by RNAi triggers and their delivery vehicles. These data are critically discussed and evaluated, taking advantage of relevant information compiled in the recently launched RNAimmuno database (http://rnaimmuno.ibch.poznan.pl).
Export Options
About this article
Cite this article as:
Olejniczak Marta, Polak Katarzyna, Galka-Marciniak Paulina and J. Krzyzosiak Wlodzimierz, Recent Advances in Understanding of the Immunological Off-Target Effects of siRNA, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192770
DOI https://dx.doi.org/10.2174/156652311798192770 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Drug Delivery Letters Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry 1, 25(OH)<sub>2</sub>D<sub>3</sub> Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes
Current Medicinal Chemistry Cell Cycle Dysregulation During Hiv Infection: Perspectives of a Target Based Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Flavonoids on Allergy
Current Pharmaceutical Design BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Chemotherapeutic Agents That Induce Mitochondrial Apoptosis
Current Cancer Drug Targets How Do Dendritic Cells Play the Role in Ischemia/Reperfusion Triggered Kidney Allograft Rejection
Current Gene Therapy Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review
Current Drug Metabolism The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Ageing as a Trait de Union Between Diabetes and Dementia for Frailty
CNS & Neurological Disorders - Drug Targets Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review
Current Pharmaceutical Biotechnology The Application of DNA Microarrays to the Study of Cancer
Current Genomics Describing the Potential Crossreactome between Mumps Virus and Spermatogenesis-Associated Proteins
Endocrine, Metabolic & Immune Disorders - Drug Targets